Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Aurrand-Lions
Host Rabbit Antigen Vimentin Synonyms VIM Immunogen Synthetic Peptide Location Cytoplasm
Two transferrin receptors
but also as a therapeutic site
Test readings: at 30 Within minutes
ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Proliferation Viability Aurrand-LionsProduct Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat
US$ 129.00
US$ 124.50
US$ 59.00
US$ 159.00
US$ 126.50
US$ 149.00
US$ 124.50
US$ 124.50
US$ 149.00
US$ 165.50
US$ 140.00
US$ 133.00
US$ 185.00
US$ 88.00
US$ 199.00
US$ 199.00
US$ 105.00